Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro, Yanhua Wang, Olga Derman, Randin Nelson, Joan Uehlinger, Kira Gritsman, R. Alejandro Sica, Noah Kornblum, Ioannis Mantzaris, Aditi Shastri, Murali JanakiramMendel Goldfinger, Amit Verma, Ira Braunschweig, Lizamarie Bachier-Rodriguez

Research output: Contribution to journalLetter

Abstract

Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.

Original languageEnglish (US)
Number of pages1
JournalJournal of hematology & oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 3 2020

Fingerprint

B-Cell Lymphoma
Cell- and Tissue-Based Therapy
Nervous System
Hepatitis
HIV
T-Lymphocytes
Hepatitis B
Antigen Receptors
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Hematopoietic Stem Cells
Lymphoma
Radiation
Transplants

Keywords

  • Axi-cel
  • CD19 CAR-T
  • CNS and CD-19 CAR-T
  • Hepatitis B and CD-19 CAR-T
  • HIV and CD-19 CAR-T

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. / Abbasi, Ahmed; Peeke, Stephen; Shah, Nishi; Mustafa, Jennat; Khatun, Fariha; Lombardo, Amanda; Abreu, Michelly; Elkind, Richard; Fehn, Karen; de Castro, Alyssa; Wang, Yanhua; Derman, Olga; Nelson, Randin; Uehlinger, Joan; Gritsman, Kira; Sica, R. Alejandro; Kornblum, Noah; Mantzaris, Ioannis; Shastri, Aditi; Janakiram, Murali; Goldfinger, Mendel; Verma, Amit; Braunschweig, Ira; Bachier-Rodriguez, Lizamarie.

In: Journal of hematology & oncology, Vol. 13, No. 1, 03.01.2020.

Research output: Contribution to journalLetter

Abbasi, A, Peeke, S, Shah, N, Mustafa, J, Khatun, F, Lombardo, A, Abreu, M, Elkind, R, Fehn, K, de Castro, A, Wang, Y, Derman, O, Nelson, R, Uehlinger, J, Gritsman, K, Sica, RA, Kornblum, N, Mantzaris, I, Shastri, A, Janakiram, M, Goldfinger, M, Verma, A, Braunschweig, I & Bachier-Rodriguez, L 2020, 'Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis', Journal of hematology & oncology, vol. 13, no. 1. https://doi.org/10.1186/s13045-019-0838-y
Abbasi, Ahmed ; Peeke, Stephen ; Shah, Nishi ; Mustafa, Jennat ; Khatun, Fariha ; Lombardo, Amanda ; Abreu, Michelly ; Elkind, Richard ; Fehn, Karen ; de Castro, Alyssa ; Wang, Yanhua ; Derman, Olga ; Nelson, Randin ; Uehlinger, Joan ; Gritsman, Kira ; Sica, R. Alejandro ; Kornblum, Noah ; Mantzaris, Ioannis ; Shastri, Aditi ; Janakiram, Murali ; Goldfinger, Mendel ; Verma, Amit ; Braunschweig, Ira ; Bachier-Rodriguez, Lizamarie. / Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. In: Journal of hematology & oncology. 2020 ; Vol. 13, No. 1.
@article{a4194128188a454caf9fd317c0dced43,
title = "Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis",
abstract = "Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80{\%}) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20{\%} of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.",
keywords = "Axi-cel, CD19 CAR-T, CNS and CD-19 CAR-T, Hepatitis B and CD-19 CAR-T, HIV and CD-19 CAR-T",
author = "Ahmed Abbasi and Stephen Peeke and Nishi Shah and Jennat Mustafa and Fariha Khatun and Amanda Lombardo and Michelly Abreu and Richard Elkind and Karen Fehn and {de Castro}, Alyssa and Yanhua Wang and Olga Derman and Randin Nelson and Joan Uehlinger and Kira Gritsman and Sica, {R. Alejandro} and Noah Kornblum and Ioannis Mantzaris and Aditi Shastri and Murali Janakiram and Mendel Goldfinger and Amit Verma and Ira Braunschweig and Lizamarie Bachier-Rodriguez",
year = "2020",
month = "1",
day = "3",
doi = "10.1186/s13045-019-0838-y",
language = "English (US)",
volume = "13",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis

AU - Abbasi, Ahmed

AU - Peeke, Stephen

AU - Shah, Nishi

AU - Mustafa, Jennat

AU - Khatun, Fariha

AU - Lombardo, Amanda

AU - Abreu, Michelly

AU - Elkind, Richard

AU - Fehn, Karen

AU - de Castro, Alyssa

AU - Wang, Yanhua

AU - Derman, Olga

AU - Nelson, Randin

AU - Uehlinger, Joan

AU - Gritsman, Kira

AU - Sica, R. Alejandro

AU - Kornblum, Noah

AU - Mantzaris, Ioannis

AU - Shastri, Aditi

AU - Janakiram, Murali

AU - Goldfinger, Mendel

AU - Verma, Amit

AU - Braunschweig, Ira

AU - Bachier-Rodriguez, Lizamarie

PY - 2020/1/3

Y1 - 2020/1/3

N2 - Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.

AB - Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FDA approval in an inner-city tertiary center in the Bronx. Eight patients (80%) had received ≥ 3 lines of therapy, six patients had received prior radiation, and seven had recurrent disease after prior autologous hematopoietic stem cell transplant (AHCT). Our cohort included one patient with HIV, two patients with hepatitis B, and two patients with CNS involvement of lymphoma. Axi-cel treatment led to significant responses with 8/10 patients achieving a complete remission at 3 months, including both patients with prior CNS involvement. The treatment was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS. One patient each with HIV and hepatitis B responded without significant toxicities. In conclusion, Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting.

KW - Axi-cel

KW - CD19 CAR-T

KW - CNS and CD-19 CAR-T

KW - Hepatitis B and CD-19 CAR-T

KW - HIV and CD-19 CAR-T

UR - http://www.scopus.com/inward/record.url?scp=85077480078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077480078&partnerID=8YFLogxK

U2 - 10.1186/s13045-019-0838-y

DO - 10.1186/s13045-019-0838-y

M3 - Letter

C2 - 31900191

AN - SCOPUS:85077480078

VL - 13

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

ER -